Replies to post #356820 on Innovation Pharmaceuticals Inc (IPIX)

[ME93]

Layman’s question: Is it possible that the anti-bacterial and anti-inflammatory properties of B, can make it a more effective therapeutic?

I know we need data from P2, but just asking about the possibility based on existing lab data.

[loanranger]

That's the original "peer reviewed journal" from a few months ago.

[Blue Fin]

OG, could you provide a link: " The testing done at GMU showed that remdesivir was more potent than brilacidin. This is inconvenient for investors in IPIX, including myself, but that is what GMU has shown us."

I remember Remdesivir and Brilacidin reducing the load by 99.98% but don't remember an independent test of Remdesivir.

[LIVED]

Some posters have been making the claim that remdesivir is “worthless” and a "fraud", yet the research done at GMU have shown it to be more potent than brilacidin.

Useless would have been the better word. "Worthless" does not apply as they are making mega bucks even when trial results show it has very little to no effect.
Brilacidin and remdesivir have different MOA's and Brilacidin is now up at bat. We only need to be a little bit better than the standard of care.

Brilacidin appears to have primarily an extracellular mechanism of action, by disrupting viral integrity and blocking viral entry. In contrast, Remdesivir—currently authorized by the FDA for emergency use against COVID-19—has an intracellular mechanism of action, affecting viral replication post-infection.